Simulating Autonomous Mobile Programs on Networks

Autonomous mobile programs (AMPs) have been proposed for load management in dynamic networks. An AMP is aware of its resource needs and periodically seeks a better location in the network to reduce execution time. AMPs have previously been measured using mobile Java Voyager on local area networks (LANs). We have constructed a simulation model of AMPs and reproduced 4 sets of experiments on homogeneous networks, i.e. networks where all locations have the same processor speed, and 2 sets of experiments on heterogeneous networks with collection of large and small AMPs. The results show that simulated collections of AMPs obtain similar balanced states to those reached in the real experiments, and have only minor differences from real experimental results. The simulation model gives an opportunity to explore the greedy effect that can be observed in the real experiments. This gives us confidence to apply the simulation model for further investigation of AMP behaviour, including behaviours on wide area networks

Ontology-based quality attributes prediction in component-based development

Despite the success that Component-Based Development (CBD) has achieved so far, component mismatch remains as a big obstacle for wider and smoother component reuse. Mismatch refers that the selected component does not satisfy the functional requirements, or that it fails the user’s expectation in terms of the Quality Attributes (QAs) of the component-based system. This allows us the potential to predict the quality attributes of a software system by analysing the result of component retrieval. In this paper, applicable quality attributes for prediction are selected by investigating existing software quality attributes. A novel ontology-based approach was proposed to achieve precise component retrieval and quality attribute prediction. The approach contains three steps: the first is to develop a Quality Attributes Oriented Component Specification ontology model (QAOCS), where applicable QAs related knowledge of application domains were integrated into the ontology. The second is to establish an ontology-based QAs oriented component retrieval method to retrieve components according to the reuse requirements. The third is to predict the quality attributes of component-based system on the basis of the matching information. Based on these three steps, a prototype tool with an example component repository was built to verify and scale up the approach

Systems Reengineering Patterns

s of a successful solution, with the contexts in which it works. Most work on systems reengineering so far has attempted to provide a methodology for reengineering. Examples include [4], [16], and Unisys' Refits. However, no reengineering methodology has yet had anything like the impact of the successful development methodologies. Possible problems (apart from immaturity of the field) are: Organisations and their reengineering projects differ very widely. One organisation's legacy system may be a small but vital and unmaintainable collection of spreadsheets, another's a system consisting of millions of lines of code. Reengineering problems arise at many different levels, from the architecture of huge systems to the detailed structure of small components. A methodology must either make (explicit or implicit) restrictions on its scope, or be huge, with most of the methodology being irrelevant to any given reengineering project. The potential user of the me

Chandra Detections of Two Quiescent Black Hole X-Ray Transients

Using the Chandra X-ray Observatory, we have detected the black hole transients V4641 Sgr and XTE J1859+226 in their low luminosity, quiescent states. The 0.3-8 keV luminosities are (4.0^(+3.3)_(-2.4))E31 (d/7 kpc)^2 erg/s and (4.2^(+4.8)_(-2.2))E31 (d/11 kpc)^2 erg/s for V4641 Sgr and XTE J1859+226, respectively. With the addition of these 2 systems, 14 out of the 15 transients with confirmed black holes (via compact object mass measurements) now have measured quiescent luminosities or sensitive upper limits. The only exception is GRS 1915+105, which has not been in quiescence since its discovery in 1992. The luminosities for V4641 Sgr and XTE J1859+226 are consistent with the median luminosity of 2E31 erg/s for the systems with previous detections. Our analysis suggests that the quiescent X-ray spectrum of V4641 Sgr is harder than for the other systems in this group, but, due to the low statistical quality of the spectrum, it is not clear if V4641 Sgr is intrinsically hard or if the column density is higher than the interstellar value. Focusing on V4641 Sgr, we compare our results to theoretical models for X-ray emission from black holes in quiescence. Also, we obtain precise X-ray positions for V4641 Sgr and XTE J1859+226 via cross-correlation of the X-ray sources detected near our targets with IR sources in the 2 Micron All-Sky Survey catalog.Comment: 4 pages, Accepted by ApJ Letter

No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing.

BACKGROUND: BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, and previous studies have also suggested that rare protein truncating variants in BRIP1 are associated with an increased risk of breast cancer. These studies have led to inclusion of BRIP1 on targeted sequencing panels for breast cancer risk prediction. METHODS: We evaluated a truncating variant, p.Arg798Ter (rs137852986), and 10 missense variants of BRIP1, in 48 144 cases and 43 607 controls of European origin, drawn from 41 studies participating in the Breast Cancer Association Consortium (BCAC). Additionally, we sequenced the coding regions of BRIP1 in 13 213 cases and 5242 controls from the UK, 1313 cases and 1123 controls from three population-based studies as part of the Breast Cancer Family Registry, and 1853 familial cases and 2001 controls from Australia. RESULTS: The rare truncating allele of rs137852986 was observed in 23 cases and 18 controls in Europeans in BCAC (OR 1.09, 95% CI 0.58 to 2.03, p=0.79). Truncating variants were found in the sequencing studies in 34 cases (0.21%) and 19 controls (0.23%) (combined OR 0.90, 95% CI 0.48 to 1.70, p=0.75). CONCLUSIONS: These results suggest that truncating variants in BRIP1, and in particular p.Arg798Ter, are not associated with a substantial increase in breast cancer risk. Such observations have important implications for the reporting of results from breast cancer screening panels.The COGS project is funded through a European Commission's Seventh Framework Programme grant (agreement number 223175 - HEALTH-F2-2009-223175). BCAC is funded by Cancer Research UK [C1287/A10118, C1287/A12014] and by the European Community´s Seventh Framework Programme under grant agreement number 223175 (grant number HEALTH-F2-2009-223175) (COGS). Funding for the iCOGS infrastructure came from: the European Community's Seventh Framework Programme under grant agreement n° 223175 (HEALTH-F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A 10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/A10692, C8197/A16565), the National Institutes of Health (CA128978) and Post-Cancer GWAS initiative (1U19 CA148537, 1U19 16 CA148065 and 1U19 CA148112 - the GAME-ON initiative), the Department of Defense (W81XWH-10-1- 0341), the Canadian Institutes of Health Research (CIHR) for the CIHR Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund. This study made use of data generated by the Wellcome Trust Case Control consortium. Funding for the project was provided by the Wellcome Trust under award 076113. The results published here are in part based upon data generated by The Cancer Genome Atlas Project established by the National Cancer Institute and National Human Genome Research Institute.This is the author accepted manuscript. The final version is available from BMJ Group at http://dx.doi.org/10.1136/jmedgenet-2015-103529

7q21-rs6964587 and breast cancer risk: an extended case–control study by the Breast Cancer Association Consortium

Background: Using the Breast Cancer Association Consortium, the authors previously reported that the single nucleotide polymorphism 7q21-rs6964587 (AKAP9-M463I) is associated with breast cancer risk. The authors have now assessed this association more comprehensively using 16 independent case–control studies. Methods: The authors genotyped 14 843 invasive case patients and 19 852 control subjects with white European ancestry and 2595 invasive case patients and 2192 control subjects with Asian ancestry. ORs were estimated by logistic regression, adjusted for study. Heterogeneity in ORs was assessed by fitting interaction terms or by subclassifying case patients and applying polytomous logistic regression. Results: For white European women, the minor T allele of 7q21-rs6964587 was associated with breast cancer risk under a recessive model (OR 1.07, 95% CI 1.00 to 1.13, p=0.04). Results were inconclusive for Asian women. From a combined analysis of 24 154 case patients and 33 376 control subjects of white European ancestry from the present and previous series, the best-fitting model was recessive, with an estimated OR of 1.08 (95% CI 1.03 to 1.13, p=0.001). The OR was greater at younger ages (p trend=0.01). Conclusion: This may be the first common susceptibility allele for breast cancer to be identified with a recessive mode of inheritance

No evidence that protein truncating variants in BRIP1 are associated with breast cancer risk: implications for gene panel testing

Background: BRCA1 interacting protein C-terminal helicase 1 (BRIP1) is one of the Fanconi Anaemia Complementation (FANC) group family of DNA repair proteins. Biallelic mutations in BRIP1 are responsible for FANC group J, and previous studies have also suggested that rare protein truncating variants in BRIP1 are associated with an increased risk of breast cancer. These studies have led to inclusion of BRIP1 on targeted sequencing panels for breast cancer risk prediction. Methods: We evaluated a truncating variant, p.Arg798Ter (rs137852986), and 10 missense variants of BRIP1, in 48 144 cases and 43 607 controls of European origin, drawn from 41 studies participating in the Breast Cancer Association Consortium (BCAC). Additionally, we sequenced the coding regions of BRIP1 in 13 213 cases and 5242 controls from the UK, 1313 cases and 1123 controls from three population-based studies as part of the Breast Cancer Family Registry, and 1853 familial cases and 2001 controls from Australia. Results: The rare truncating allele of rs137852986 was observed in 23 cases and 18 controls in Europeans in BCAC (OR 1.09, 95% CI 0.58 to 2.03, p=0.79). Truncating variants were found in the sequencing studies in 34 cases (0.21%) and 19 controls (0.23%) (combined OR 0.90, 95% CI 0.48 to 1.70, p=0.75). Conclusions: These results suggest that truncating variants in BRIP1, and in particular p.Arg798Ter, are not associated with a substantial increase in breast cancer risk. Such observations have important implications for the reporting of results from breast cancer screening panels